About Ayal Ronen
This author has not written his bio yet.
But we are proud to say that Ayal Ronen contributed 424 entries already.
Entries by Ayal Ronen
UPDATE: Congress on Track to Reauthorize the SBIR and STTR Programs
SBIR/STTR programs will expire if Congress doesn’t reauthorize by September 30th. Senator Paul blocked reauthorization because of security problems. New provisions added to address security concerns.
Bill passed Senate, expected to pass House. SBIR/STTR programs extended for three more years.
Update on Biden’s $2-Billion Biotechnology Boost
President Biden established the National Biotechnology and Biomanufacturing Initiative to drive research and development to “Solve Our Greatest Challenges.” The Initiative’s goals strongly suggest more non-dilutive funding opportunities in grants for R&D as well as contracts related to bioproducts and biomanufacturing.
SBIR/STTR Programs Could Expire Sept. 30
SBIR/STTR programs could expire Sept 30. Reauthorization opposed by Rand Paul and others. SBIR/STTR grants enable commercialization of federally funded research and have broad benefits that improve life for all Americans as well as billions around the globe.
Biden Establishes National Biotechnology and Biomanufacturing Initiative with Executive Order
President Biden established the National Biotechnology and Biomanufacturing Initiative to drive research and development to “Solve Our Greatest Challenges.” The Initiative’s goals strongly suggest more non-dilutive funding opportunities in grants for R&D as well as contracts related to bioproducts and biomanufacturing.
Is Non-Dilutive Funding the Key to Extending Runway in Biopharma and Biotech?
Since venture investment in life science companies began to slump in 2021, biopharma companies have tightened their belts notch by notch to squeeze more utility from each cent and extend their runways. In this environment, non-dilutive funding has become ever more important, especially for small and mid-sized companies.
BioPharm America, an EBD event, Sept 28-29, Boston (& Virtual)
BioPharm America, where innovators partner to fuel the future of drug development.
BioForward, Sept 27, Oxford
The BioForward conference is designed to help life science companies connect with the best service providers. Each R&D company receives first ticket free. 10% off other tickets using our code…
How Non-Dilutive Funding Leads to Equity Investment: The Story of Enalare
Each $1 of non-dilutive funding from NIH translates into $8.38 of private sector investment in R&D. Companies which win non-dilutive funding from organizations such as BARDA, NIH, NSF, and CDMRP, are more likely to receive major equity investments.
Website Links
Address
FreeMind Group
6 Liberty Square #2783
Boston, MA 02109